The long-term consequences of pulmonary tuberculosis and respiratory viruses on lung health in young South African children
Project Number5K43TW011028-05
Contact PI/Project LeaderVAN DER ZALM, MARIEKE MARGREET
Awardee OrganizationSTELLENBOSCH UNIVERSITY
Description
Abstract Text
PROJECT SUMMARY
Candidate: Dr. van der Zalm is highly motivated to find innovative feasible solutions to improve the long-term
lung health outcomes in vulnerable children in settings with high burden of tuberculosis (TB) and other
respiratory infectious diseases. Her overall career development goal is to become an independent clinician
scientist with expertise in the design, implementation and analysis of translational clinical research, in order to
effectively address high-priority lung health issues in children living in low- and middle- income countries
(LMICs). Her overall goal is supported by three specific training aims: 1) designing and implementing research
focused on a unique and as yet unaddressed aspect of clinical TB research in children. This includes an in-
depth understanding of longitudinal data analysis and advanced biostatistics required to analyse this rich and
unique cohort with long-term outcomes, 2) to develop into a contents expert and thought leader in pediatric TB
and lung health assessment, and 3) to develop the skills to translate key research findings into relevant clinical
guidelines to impact on policies and practice. This combination of analytical, clinical and translational skills is
required to maximize the impact of translational clinical research in children, especially those in LMICs, where
infectious disease contribute to significant morbidity including long-term lung health outcomes. Dr. van der
Zalm has strong institutional support and has assembled a strong US and international mentoring team highly
experienced in all critical aspects of pediatric TB and lung health research.
Research project: Despite increasing awareness of post-TB respiratory morbidity in adults, there is no data in
children. An estimated 5-10 million children had survived TB between 2000 and 2017 and are at potential risk
of post-TB lung sequelae. The pre- and early postnatal years are the most critical period of lung development.
Therefore, PTB events early in life due to this chronic disease, could have devastating long-term
consequences on lung health of young children.
I propose to investigate the impact of TB on lung health using an established cohort study, “Umoya,” which
provides a unique opportunity to characterize the long-term effect of PTB and other common respiratory
pathogens on lung health in children investigated for PTB, with well-characterized control groups. Specific aim
1 will investigate the long-term respiratory morbidity and evaluate risk factors for poor respiratory outcomes in
children investigated for PTB. Specific aim 2 will describe lung function trajectories in South African children
investigated for PTB. My proposed research aims to define and characterize the spectrum of respiratory
morbidity in children who have survived PTB. An improved understanding of the impact of PTB and other
modifying factors, e.g. viral co-infections, on lung development in children will inform future strategies to
prevent respiratory illness later in life. Through this research I will obtain relevant research skills, establishing
myself as an independent researcher and will use this unique dataset to apply for future R01 grant funding.
Public Health Relevance Statement
PROJECT NARRATIVE
Despite increasing awareness of post-tuberculosis respiratory morbidity in adults, there is no data in children
yet. An estimated 5-10 million children survived tuberculosis between 2000 and 2017 and are at potential risk
of lung sequelae. An improved understanding of the impact of tuberculosis and respiratory virus infections on
lung health in children could inform strategies to significantly improve the health of young children.
NIH Spending Category
No NIH Spending Category available.
Project Terms
2 year oldAddressAdenovirusesAdultAffectAfricanAftercareAgeAirway ResistanceAwarenessBiologicalBiometryChildChild HealthChildhoodChronic DiseaseClinicalClinical ResearchCohort StudiesCommunicable DiseasesControl GroupsDataData AnalysesData SetDiffusionDiseaseEnrollmentEventExclusionFundingFutureGoalsGrantGuidelinesHIVHealthHeightHospitalizationInfectionInstitutionInternationalInterventionInvestigationLifeLiteratureLong-Term EffectsLongitudinal cohortLungLung DiseasesMeasuresMentorsMethodsMicrobiologyModelingMorbidity - disease rateMycobacterium tuberculosisNasopharynxOscillometryOutcomeOutcome MeasurePhysical ExaminationPlethysmographyPoliciesPulmonary TuberculosisPulmonary function testsQuality of lifeQuestionnairesRadiology SpecialtyRecording of previous eventsResearchResearch PersonnelResearch Project GrantsResistanceRespiratory DiseaseRespiratory syncytial virusRiskRisk FactorsSamplingScientistSeveritiesSmokingSouth AfricaSouth AfricanSpirometryTechniquesTestingThoracic RadiographyTidal VolumeTimeTrainingTranslatingTuberculosisUnited States National Institutes of HealthVaccinationViralViral Respiratory Tract InfectionVulnerable PopulationsWeightaspirateburden of illnesscareercareer developmentclinical examinationclinical translationclinically relevantco-infectioncohortcritical perioddesignexperiencefollow-upfunctional outcomeshealth assessmenthigh riskimprovedinnovationinterestlow and middle-income countrieslung developmentlung healthpathogenpostnatalpreventprospectivepulmonary functionrespiratoryrespiratory healthrespiratory infection virusrespiratory morbidityrespiratory pathogenrespiratory virusskillstranslational impactventilationviral detection
John E. Fogarty International Center for Advanced Study in the Health Sciences
CFDA Code
989
DUNS Number
569118040
UEI
C6CHDMTANVS3
Project Start Date
01-August-2020
Project End Date
31-July-2025
Budget Start Date
01-August-2024
Budget End Date
31-July-2025
Project Funding Information for 2024
Total Funding
$112,523
Direct Costs
$104,188
Indirect Costs
$8,335
Year
Funding IC
FY Total Cost by IC
2024
John E. Fogarty International Center for Advanced Study in the Health Sciences
$112,523
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5K43TW011028-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5K43TW011028-05
Patents
No Patents information available for 5K43TW011028-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5K43TW011028-05
Clinical Studies
No Clinical Studies information available for 5K43TW011028-05
News and More
Related News Releases
No news release information available for 5K43TW011028-05
History
No Historical information available for 5K43TW011028-05
Similar Projects
No Similar Projects information available for 5K43TW011028-05